SEC Form 4 · accession 0001209191-16-097997
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph A Mollica
Director
Period of report
Feb 10, 2016
Accepted (ET)
Feb 12, 2016 · 3:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 10, 2016 | M | 20,000 | $3.07 | A | 39,175 | D | |
| Common StockF1 | Feb 10, 2016 | F | 1,821 | $33.70 | D | 37,354 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $3.07 | Feb 10, 2016 | M | 20,000 | D | Jun 29, 2009 | May 29, 2016 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 29, 2009, which, if unexercised, would have expired on May 29, 2016. The option exercises are reported on Table II. These option exercises were pursuant to a new issuance arrangement effected under the issuer's equity incentive plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.07) was subtracted from the February 10, 2016 market close price ($33.70) and this net amount of ($30.63) was then multiplied by the number of options (20,000), with the resulting amount then divided by the market close price to result in a net issuance of 18,179 shares to optionee. The 1,821 shares underlying the remaining portion of the options are not available for reissuance, and no shares are sold into the market as part of the exercise in connection with net issuance program.